NYMX
NASDAQ : NYMX

NYMX

October 12, 2005 11:14 ET

Nymox Reports Second Positive Interim Safety Results in Pivotal Trial of New Drug For Benign Prostatic Hyperplasia

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Oct 12, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce today that the second interim safety analysis of its ongoing multi-center Phase 2 trial of NX-1207 has revealed no serious drug side effects. NX-1207 is Nymox's lead drug candidate for the treatment of benign prostatic hyperplasia (BPH) which the company believes shows good promise as a potential first-line treatment for BPH. In the two previously completed trials in the U.S., the drug has shown excellent efficacy without serious side effects. The Company's large Phase 2 trial is expected to be completed later this year.

In the completed Phase 1-2 trials to date, the subjects treated with NX-1207 showed statistically significant overall mean symptom improvement and shrinkage in prostate size. There were no serious adverse events from the drug in these trials. Subjects that were followed for up to two years post-treatment showed even further statistically significant symptom improvement.

BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    www.nymox.com